More on BAYN
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.01 |
|
|||
| Open | $61.11 | ||||
| 52 Wk High | $0.04 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $0.01 | ||||
| Day Low | $0.01 | ||||
| P/E | 0.00 | ||||
| EPS | $-8.34 | ||||
| Volume | 358,028 | ||||
- Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
- ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
- Bayer to present cancer trial data at ASCO 2026 meeting
- ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
- Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
- Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
- FDA grants priority review for Bayer's asundexian stroke drug
- Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
- FDA grants priority review for Bayer's HYRNUO lung cancer application
- U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
Entities mentioned with BAYN
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Credit Suisse | View Related Stories »
- IPO | View Related Stories »
- JPMorgan | View Related Stories »
- S1 | View Related Stories »
- Show More...
